Longevity & cellular health

"Longevity" and "anti-ageing" are among the most marketed and least evidenced peptide categories. The compounds here have genuine mechanistic research behind them, but human evidence for actually slowing ageing or extending lifespan is effectively absent.

Epitalon is a synthetic tetrapeptide claimed to activate telomerase and influence the pineal gland; its evidence is dominated by a single research group, largely unreplicated, and often conflates a pineal extract with the pure peptide. MOTS-c is a mitochondrial-derived peptide with interesting metabolic and exercise-mimetic effects in cell and animal studies, but human data are limited to genetic-association observations, with no therapeutic trials of the native peptide. SS-31 (elamipretide) is the most clinically advanced: it targets mitochondrial cardiolipin and has been through many human trials, but several missed their primary endpoints, and its 2025 FDA approval is a narrow, accelerated one for the ultra-rare Barth syndrome, not for general longevity.

Conditions people ask about

Popular videos and high-claim content in this area promise to "reverse", "reset", or "cure" ageing — telomere injections, "zombie cell" clearers, gene-expression age resets, and exercise-in-a-vial mitochondrial peptides sold as a longevity stack that adds years to your life. No compound on this site is an approved treatment for any condition below, and the dramatic "reversal" claims are not backed by controlled human outcome trials we could locate. That is a statement about what the trials show today, not a promise that these claims are false: much of the relevant work in this field is hard to reach — paywalled journals, Russian and other regional literature, clinician experience, conference abstracts, and unpublished or proprietary data — so a missing citation here means "not established in the sources we could search", not "disproven". The notes below answer the searches people actually run, honestly, and hold that line: no endorsement, no dosing. Aging and age-related disease are matters for a licensed clinician and a proper diagnosis — a research peptide is not a substitute for one.

Biological aging / "longevity"

What's claimed: that a peptide stack can slow, "reverse", or "reset" biological age — telomere-lengthening injections, senescent-cell ("zombie cell") clearers, gene-expression "age resets", and mitochondrial "exercise mimetics" marketed together as a protocol that extends lifespan.

The evidence reality: no compound in this inventory is an approved anti-aging or lifespan-extension treatment, and none can be under current rules — the FDA does not recognise aging itself as a disease, so drugs are only ever approved for specific conditions, never for "longevity" [Human]. Most of the dramatic claims rest on cell-culture and rodent data, or on a single Russian research group's small, unblinded mortality studies that have not been replicated to Western Phase 3 standards; we found no controlled human trial in the accessible literature showing that any of these compounds extends human lifespan or "reverses" biological age — which is a limit of what is indexed and reachable, not a demonstration that they do not. Where a mitochondrial peptide has reached regulatory approval, it was a narrow, conditional approval for a specific rare disease, not for aging. This is a matter for a licensed clinician and a proper diagnosis — a research peptide is not a substitute.

Compounds discussed in this context:

• Epitalon — a synthetic pineal tetrapeptide (a Khavinson "bioregulator") marketed as a telomerase-activating longevity peptide. Telomere lengthening is real in human cell lines [In vitro], and it comes out of a Russian peptide-bioregulator school that reports long-follow-up mortality reductions in elderly cohorts — that evidence is older, small, and dominated by one research group, and has not been replicated to Western Phase 3 standards, though that partly reflects how little of this regional literature has been reproduced or translated [Human, low quality]. Not approved for aging anywhere; much of the strongest longevity signal traces to the pineal extract (epithalamin) it was derived from rather than the pure synthetic peptide.
• Thymalin — a thymic bioregulator preparation from the same Russian research programme; it appears in a Neuroendocrinology Letters (2003) study that followed ~266 elderly people over 6–8 years and reported reduced mortality, with the largest reduction when combined with the pineal preparation epithalamin [Human, low quality — small, unblinded, single-lab, not independently replicated in the sources we could access]. Discussed for immune "restoration" with age. Not FDA- or EMA-approved for longevity; the wider Khavinson family is marketed similarly and rests on the same limited, largely regional evidence base.
• SS-31 (elamipretide) — a mitochondria-targeting peptide, and the most clinically advanced compound here: it has been through many human trials, and in September 2025 the FDA granted it accelerated approval (as elamipretide HCl, brand Forzinity) — but that approval is narrow and conditional, only to improve muscle strength in the ultra-rare Barth syndrome, resting on an intermediate endpoint and subject to confirmatory study [Human]. Several of its randomised trials — in mitochondrial myopathy, heart failure, and dry AMD — missed their primary endpoints. It is not an approved anti-aging, longevity, or general heart-failure drug, and community framing of it as a general "anti-aging" mitochondrial peptide runs ahead of the actual, disease-specific evidence.
• MOTS-c — a mitochondrial-derived peptide whose endogenous levels rise with exercise and fall with age, and which is associated with longevity in some human observational data [Human, associational]. Late-life dosing improved physical capacity in mice [Animal]. Marketed as an "exercise mimetic" for healthspan; we found no controlled human trial of MOTS-c injection for aging outcomes in the accessible literature.
• Humanin — a mitochondrial-derived peptide studied for cytoprotection; endogenous levels decline with age, and human data are largely observational [Human, associational]. Cited in longevity discussions for cellular stress resistance; the accessible evidence is largely mechanistic and observational — we located no completed human therapeutic trial of administered humanin, and none showing it slows aging or extends lifespan.
• NAD+ — NAD+ (and precursors like NMN/NR) is the community's central "longevity" molecule, though it is a redox coenzyme, not a peptide. Supplementation reliably raises blood NAD+ and appears well tolerated in small human trials [Human], and extends lifespan in mice [Animal] — but we found no human evidence that it extends lifespan or reverses aging, and metabolic-benefit results in people are small and inconsistent. IV/injectable NAD+ is not FDA- or EMA-approved; oral NAD+ and its precursors are sold as unapproved dietary supplements with little published human efficacy data for aging itself.
• GHK-Cu — a copper tripeptide famous for a gene-expression analysis suggesting it shifts aged-cell expression toward younger patterns [In vitro]. Its documented human evidence is for skin — collagen density, wound healing [Human] — not systemic longevity; the "resets hundreds of aging genes" story is a cell/database finding, and we located no controlled human trial of GHK-Cu as a lifespan or biological-age intervention.
• FOXO4-DRI — a designed senolytic peptide meant to clear "zombie" (senescent) cells by disrupting the FOXO4–p53 interaction. It reduced senescent-cell burden and restored some tissue function in mice and cell culture [Animal, In vitro], but as of 2026 we found no published human trials [preclinical; no controlled human evidence located]. Effectively preclinical; the senolytic field's human data comes from other agents, not this peptide.
• 5-Amino-1MQ — an NNMT inhibitor (a small molecule, not a peptide) marketed as a metabolic / "exercise-mimetic" longevity compound. In diet-induced obese mice it reduced body weight and fat mass [Animal]; the accessible evidence base is mechanistic and rodent/cell only [Animal, In vitro], with no published human trials and no human PK data for aging or metabolic outcomes that we could find [no controlled human evidence located].
• SLU-PP-332 — an ERR agonist (a small molecule, not a peptide) promoted as "exercise in a pill" for endurance and healthspan. It improved endurance and metabolic markers and cut fat mass in mice [Animal], but it is very new and, in the accessible literature, animal-only, with no human safety or efficacy data located [no controlled human evidence located] — sold strictly as a research chemical.

Fatigue and "broken mitochondria"

High-claim videos reframe chronic tiredness and burnout as an "energy-infrastructure" failure — the mitochondria are "broken," not tired — said to be reversible in about a month with a stack of mitochondrial compounds (SS-31, MOTS-c, NAD+, CoQ10/PQQ and others), while prescribed psychiatric medicines (SSRIs, benzodiazepines, stimulants) supposedly "make it worse." The honest picture is more careful. Mitochondrial/bioenergetic dysfunction in chronic fatigue is a genuine, active research area — especially in ME/CFS and post-viral fatigue — so it should not be dismissed; but the evidence is associative and methodologically inconsistent, not a validated mechanism you can diagnose from the symptom of tiredness (a systematic review found the mitochondrial role in ME/CFS could not be established across studies; Holden et al., J Transl Med 2020) [Human/review]. No compound on this site is an approved treatment for chronic fatigue or burnout — and burnout is not even a medical diagnosis (the WHO's ICD-11 classes it as an occupational phenomenon, not an illness), while there is no FDA- or EMA-approved drug for ME/CFS at all. Tellingly, the one mitochondria-targeted peptide actually tested against a human fatigue endpoint, SS-31 (elamipretide), missed the Total Fatigue Score in its phase 3 trial (MMPOWER-3) [Human]; MOTS-c is preclinical with no human anti-fatigue data [Animal]; and NAD+ has only limited human data and no established energy benefit [Human, limited]. The confident study citations that make the "proven mechanism" case largely could not be traced or were misattributed.

Most of all this is a safety issue: persistent fatigue is a non-specific symptom that can mask treatable conditions — hypothyroidism, iron- or B12-deficiency anaemia, sleep apnoea, depression, diabetes, heart disease — so the right first move is a proper work-up by a clinician, not self-diagnosing "broken mitochondria" and self-treating with research chemicals. Nothing here is a reason to stop a prescribed medication: benzodiazepines in particular must never be stopped abruptly (sudden withdrawal can cause seizures), and any change belongs with the prescriber. Note too a concrete hazard in the wider "mitochondrial stack" — methylene blue, often promoted alongside it, is a potent MAO inhibitor that can trigger dangerous serotonin syndrome if combined with an SSRI, exactly the medication these videos tell people to abandon. A research peptide is not a substitute for a diagnosis.